RedHill Biopharma Presents Positive Oral Opaganib Phase 2 Data In COVID-19

RedHill Biopharma Ltd. (RDHL) said that it has presented the positive phase 2 safety and efficacy data for oral opaganib or Yeliva, ABC294640 in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum 2021.

Findings from the 40-patient U.S. Phase 2 study include 50% of patients treated with opaganib reached room air by Day 14 compared to 22% in the placebo group. The benefit of reaching room air by Day 14 for patients on opaganib was maintained regardless of whether the patients were receiving dexamethasone and/or remdesivir.

According to the study results, 86.4% of patients treated with opaganib were discharged from hospital by Day 14 compared to 55.6% of patients treated with placebo.

Median time to discharge was 6 days for the opaganib group compared to 7.5 days for the placebo group.

The company noted that 81.8% of opaganib patients achieved a 2-point improvement in the WHO Ordinal Scale compared to 55.6% of patients in the placebo group - achieved in a median time of 6 days versus 7.5 days, respectively.

The data, from this proof-of-concept clinical study of opaganib in patients with severe COVID-19, suggested a potential role of SK2 inhibition in combating the effects of this virus. With much more data on opaganib expected in the coming weeks, the company could make some real progress toward having access to a much-needed oral therapy for patients who currently have a paucity of options available to them, RedHill Biopharma said.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Sturtevant, Wisconsin-based BRP U.S. Inc. is recalling around 20 models of Side-by-Side vehicles citing fire risk, the U.S. Consumer Product Safety Commission. The recall involves about 34,400 units of Model Years 2020 and 2021 Can-AM Defender HD10 side-by-side vehicles. While reporting financial results for the second quarter on Friday, technology company Honeywell international Inc. (HON) raised its adjusted earnings and sales guidance for the full-year 2021, based on the second-quarter performance and management's outlook for the remainder of the year. For fiscal... Shares of Vodafone Group Plc were gaining around 2 percent in the morning trading in London after the British telecom major reported higher revenues in its first quarter. Looking ahead, the company said it is on track to deliver fiscal year 2022 guidance, with Adjusted EBITDAaL expected to be between 15.0 billion euros - 15.4 billion euros and Adjusted free cash flow of at least 5.2 billion euros
Follow RTT